Recent Publications by PDL BioPharma: |
Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.
Humanization and modification of the Fc region of anti-human CD3 mAbs have... | 1st August, 2009
| PDL BioPharma 1400 Seaport Blvd Redwood City, CA 94063, USA.
| J Neuroimmunol. 2009 Jul 25;212(1-2):65-73. Epub 2009 May 23.
DOI Direct Link |
Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.
Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have... | 26th February, 2009
| Research Department, PDL BioPharma, Redwood City, California 94063, USA.
| Immunol Invest. 2009;38(1):76-92.
DOI Direct Link |
NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures.
Recent developments in high cell density and high productivity fed-batch... | 19th November, 2008
| Process Sciences and Engineering, PDL BioPharma, Inc., 1400 Seaport Blvd,
| Biotechnol Bioeng. 2008 Nov 1;101(4):751-60.
DOI Direct Link |
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
Angiogenesis, the process by which new blood vessels form from existing... | 10th June, 2008
| PDL Biopharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.
| Invest New Drugs. 2008 Feb;26(1):7-12. Epub 2007 Sep 1.
DOI Direct Link |
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
BACKGROUND: Integrins are important adhesion molecules that regulate tumor... | 29th March, 2008
| Department of Research, PDL Biopharma, Inc,, Fremont, CA 94555, USA.
| J Transl Med. 2007 Nov 27;5:61.
DOI Direct Link |
Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies.
We have developed a mammalian cell surface display vector, suitable for... | 8th December, 2007
| PDL BioPharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.
| J Immunol Methods. 2007 Oct 31;327(1-2):40-52. Epub 2007 Aug 2.
DOI Direct Link |
Validated alternatives: is immediate implementation required? Baluride: don't get taken for a ride.
We have developed a mammalian cell surface display vector, suitable for... | 25th July, 2007
| PDL BioPharma, Fremont, CA, USA.
| Lab Anim (NY). 2007 May;36(5):13.
DOI Direct Link |
Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies.
Presented is a novel antibody production platform based on the fed-batch... | 30th June, 2007
| Process Sciences and Engineering, PDL BioPharma, Inc., 34700 Campus Drive,
| Biotechnol Bioeng. 2007 Feb 1;96(2):281-93.
DOI Direct Link |
Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies.
Presented is an antibody production platform based on the fed-batch... | 30th June, 2007
| Process Sciences and Engineering, PDL BioPharma, Inc., 34801 Campus Drive,
| Biotechnol Bioeng. 2007 Feb 1;96(2):294-306.
DOI Direct Link |
Cell based assays in drug development for biopharmaceuticals--IIR's Second Annual Conference.
We have developed a mammalian cell surface display vector, suitable for... | 9th February, 2007
| PDL Biopharma Inc, 34801 Campus Drive, Fremont, CA 94555, USA.
| IDrugs. 2006 Dec;9(12):841-5.
|
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
Integrin alpha5beta1, the principal fibronectin receptor, is an important... | 3rd February, 2007
| PDL Biopharma
| J Exp Ther Oncol. 2006;5(4):273-86.
|
Confirming human antibody responses to a therapeutic monoclonal antibody using a statistical approach.
Confirmatory assays for immunogenicity testing typically involve testing a... | 9th December, 2006
| Preclinical and Clinical Development Sciences, PDL BioPharma, Inc.,
| J Immunol Methods. 2006 Aug 31;315(1-2):80-7. Epub 2006 Aug 7.
DOI Direct Link |
